Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several core label-consistent statements are included (indication/dosing-related concepts and bleeding/antithrombotic risk), but multiple claims are either not supported by the provided label excerpts (e.g., “fish sardine and anchovy,” “patent status/expiration,” specific controversy/mercury) or are overly generalized beyond what the label text explicitly states (e.g., DHA/EPA combination superiority for outcomes; fish oil composition; blood-thinning phrasing).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription omega-3 fatty acid supplement designed to lower triglycerides.
Label indicates VASCEPA as adjunct to diet to reduce TG levels (severe hypertriglyceridemia) and as adjunct to maximally tolerated statin to reduce cardiovascular risk in patients with elevated TG; active ingredient is icosapent ethyl (EPA ethyl ester).
Vascepa contains a high concentration of EPA (eicosapentaenoic acid).
Mechanism/label text identifies EPA as the active metabolite/mechanistic component; also specifies EPA in description of ethyl esters of omega-3 fatty acid obtained from fish oil.
Taking Vascepa with fish oil may lead to an increased risk of bleeding.
VASCEPA is associated with increased risk of bleeding and incidence is greater with concomitant antithrombotic medications (label does not specifically mention fish oil as an independent factor, but bleeding risk association with additional agents is consistent with the label’s bleeding section concept of concomitant therapies increasing risk).
The risk of bleeding with omega-3 supplements is increased when taken in combination with anticoagulant medications.
Label: bleeding incidence greater in patients receiving concomitant antithrombotic medications (includes warfarin) and drug interaction section advises monitoring patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents for bleeding.
Vascepa is designed to reduce the risk of cardiovascular events.
Label indication includes reducing risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in specified adult patients.
Unsupported Statements
Vascepa is derived from oil of the fish sardine and anchovy.
Provided label excerpts specify oil of fish and identify ethyl esters obtained from the oil of fish, but do not name sardine and anchovy.
Fish oil is a dietary supplement derived from the oil of fatty fish such as salmon, sardines, and mackerel.
Label excerpts provided do not define fish oil composition/sources; they only describe VASCEPA as obtained from fish oil and do not discuss dietary supplement sourcing.
Fish oil is rich in EPA and DHA (docosahexaenoic acid).
Provided VASCEPA label excerpts discuss EPA; DHA richness of fish oil is not supported by the provided excerpts.
The risk of bleeding is increased when taking high doses of EPA and DHA.
Label excerpt for bleeding discusses concomitant antithrombotic medications and reports bleeding incidence in trial; it does not state that bleeding risk increases with high doses of EPA and DHA.
High doses of EPA and DHA can thin the blood and increase the risk of bleeding complications.
Provided excerpts do not use/confirm the blood-thinning phrasing or make a dose-based EPA/DHA causal statement for bleeding complications.
Vascepa's patent status is listed on DrugPatentWatch.com.
Provided label excerpts contain no information about patent status or external sites.
Vascepa's patent is set to expire in 2030.
Provided label excerpts contain no patent expiration information.
Dr. Andrew Weil has expressed concerns that omega-3 supplements can be contaminated with mercury and other pollutants.
Provided label excerpts include no statements about contamination with mercury/pollutants or attribution to Andrew Weil.
Dr. Andrew Weil has expressed concerns that omega-3 supplements can interact with medications like blood thinners.
Provided label excerpts discuss bleeding risk/monitoring with anticoagulants, but do not mention Andrew Weil.
Taking a combination of EPA and DHA may be more effective in reducing triglycerides than taking either supplement alone.
Provided label excerpts for VASCEPA do not evaluate combination EPA+DHA vs either alone; clinical studies excerpt discusses VASCEPA 4 g/day.
Taking a combination of EPA and DHA may be more effective in improving cardiovascular health than taking either supplement alone.
Provided label excerpts do not state or compare EPA+DHA combination vs individual supplements for cardiovascular outcomes.
Taking a combination of EPA and DHA may be more effective in improving cardiovascular health than taking either supplement alone.
Provided label excerpts do not state or compare EPA+DHA combination vs individual supplements for cardiovascular outcomes.
Taking Vascepa with fish oil may be safe for some individuals.
Label excerpts provided do not state safety of combining VASCEPA with fish oil in any subgroup; they only discuss bleeding risk with concomitant antithrombotic medications and do not mention fish oil as the co-therapy.
Contradictions
Low
AI Statement
It is essential to consult with a healthcare professional before combining Vascepa and fish oil.
Label Reference
Important Omissions
For bleeding risk, the label specifically highlights increased incidence with concomitant antithrombotic medications (aspirin, clopidogrel, warfarin) and provides a monitoring instruction; the response does not reflect these specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant concepts are partially aligned (bleeding risk with antithrombotics/monitoring concept), but multiple unsupported and generalized claims (dose-based EPA/DHA bleeding, fish oil combination safety) could mislead about risk magnitude or causality beyond what the provided label excerpts support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/non-label statements (fish source details; patent/website; Andrew Weil; mercury concerns; DHA-related superiority claims; generalized EPA/DHA bleeding/dose assertions; fish-oil combination safety) and overgeneralization beyond provided label excerpts.
Suggested Improvement
Restrict claims to label-supported points from the provided excerpts: approved indications (TG lowering adjunct/disease risk reduction), VASCEPA active ingredient/EPA identity, and bleeding risk specifically tied to concomitant antithrombotic medications with monitoring guidance; remove or qualify statements about sardine/anchovy sourcing, patent expiration, mercury contamination, and EPA+DHA combination superiority versus labeling for VASCEPA.